세포 분석 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 수법별, 프로세스별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Cell Analysis Market Size & Trends:

The global cell analysis market size was estimated at USD 31.59 billion in 2024 and is projected to grow at a CAGR of 10.03% from 2025 to 2030. This growth can be attributed to the increasing prevalence of chronic diseases, advancements in cell analysis technologies, and the growing number of drug discovery activities. Cell analysis has emerged as an important tool for the identification of potential therapies and treatments for chronic diseases. Thus, the increasing prevalence of chronic diseases such as cardiovascular diseases, cancer, autoimmune diseases, neurological disorders, and others can drive the demand for cell analysis. According to the American Cancer Society, over 2 million new cancer cases are expected to be diagnosed in the U.S. in 2024.

Cell analysis has witnessed an increase in its application, from early-stage cancer diagnostics to the development of cancer-associated therapies and tools, which has further increased its popularity in the oncology sector. The players operating in the oncology sector are increasing their efforts for advancements in cell analysis to develop advanced therapies and treatments. For instance, in March 2024, a cancer diagnostics company, Serum Detect, was set to launch the T-cell analysis approach for early cancer detection at the American Association for Cancer Research (AACR). Such increasing efforts by healthcare companies to increase the application of cell analysis are anticipated to drive market growth over the forecast period.

Moreover, technological advancements in cell analysis have enabled the development of automated cell analysis systems that offer results with better accuracy and efficiency. Similarly, the development of advanced technologies such as automated cell imaging, cell counting, and cell sorters allows researchers to study cells on a much larger scale. For instance, in July 2024. NanoCellect Biomedical announced the launch of VERLO, an image-guided cell sorter. This cell-sorter allows the researchers to distinguish & sort interacting cells, enabling precise characterization of cell subsets & validation of their functional phenotypes without disturbing the cell interactions. Such advancements in cell analysis technologies are anticipated to increase demand and drive market growth over the forecast period.

In addition to this, the adoption of cell cycle analysis has significantly increased in drug discovery to analyze the associated complexities. Similarly, the increasing advancements in cell biology, molecular biology, bioinformatics, proteomics, and genomics have increased the significance of utilizing cell-based assays in the drug development process. Cell-based assays offer an alternative approach to the conventional methods of toxicity and drug safety testing and allow researchers to identify problems with tested compounds in early screening through cytotoxicity and cell deaths. Thus, the increasing drug discovery activities owing to the rising need for advanced treatments are anticipated to increase the demand for cell-based assays, thereby driving the market growth.

Global Cell Analysis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global cell analysis market report based on product & service, technique, process, end-use, and region.

• Product & Service Outlook (Revenue, USD Million, 2018 - 2030)
• Reagents & Consumables
• Instruments
• Accessories
• Software
• Service
• Technique Outlook (Revenue, USD Million, 2018 - 2030)
• Flow Cytometry
• PCR
• Cell Microarrays
• Microscopy
• Spectrophotometry
• High Content-Screening
• Other Techniques
• Process Outlook (Revenue, USD Million, 2018 - 2030)
• Cell Identification
• Cell Viability
• Cell Signaling Pathways
• Cell Proliferation
• Cell Counting
• Cell Interaction
• Cell Structure Study
• Single-cell Analysis
• Others
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinical Testing Laboratories
• Academic & Research Institutes
• Other
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service Segment
  • 1.2.2. Technique Segment
  • 1.2.3. Process Segment
  • 1.2.4. End use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Cell Analysis Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases
    • 3.2.1.2. Advancements in cell analysis technologies
    • 3.2.1.3. Growing number of drug discovery activities
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Complexity of cell analysis techniques
• 3.3. Cell Analysis Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cell Analysis Market: Product & Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Cell Analysis Market Product & Service Movement Analysis
• 4.3. Global Cell Analysis Materials Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
• 4.4. Reagents & Consumables
  • 4.4.1. Reagents & Consumables market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Instruments
  • 4.5.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Accessories
  • 4.6.1. Accessories market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Software
  • 4.7.1. Software market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Service
  • 4.8.1. Service market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Cell Analysis Market: Technique Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Cell Analysis Market Technique Movement Analysis
• 5.3. Global Cell Analysis Materials Market Size & Trend Analysis, by Technique, 2018 to 2030 (USD Million)
• 5.4. Flow Cytomtery
  • 5.4.1. Flow Cytomtery market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. PCR
  • 5.5.1. PCR market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Cell Microarrays
  • 5.6.1. Cell Microarrays market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Microscopy
  • 5.7.1. Microscopy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Spectrophotometry
  • 5.8.1. Spectrophotometry market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. High Content-Screening
  • 5.9.1. High Content-Screening market estimates and forecasts 2018 to 2030 (USD Million)
• 5.10. Other Techniques
  • 5.10.1. Other Techniques market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Cell Analysis Materials Market: Process Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Cellular Starting Materials Market Process Movement Analysis
• 6.3. Global Cellular Starting Materials Market Size & Trend Analysis, by Process, 2018 to 2030 (USD Million)
• 6.4. Cell Identification
  • 6.4.1. Cell Identification market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Cell Viability
  • 6.5.1. Cell Viability market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Cell Signaling Pathways
  • 6.6.1. Cell Signaling Pathwaysmarket estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Cell Proliferation
  • 6.7.1. Cell Proliferation market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Cell Counting
  • 6.8.1. Cell Counting market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Cell Interaction
  • 6.9.1. Cell Interaction market estimates and forecasts 2018 to 2030 (USD Million)
• 6.10. Cell Structure Study
  • 6.10.1. Cell Structure Study market estimates and forecasts 2018 to 2030 (USD Million)
• 6.11. Single-cell Analysis
  • 6.11.1. Single-cell Analysis market estimates and forecasts 2018 to 2030 (USD Million)
• 6.12. Others
  • 6.12.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Cellular Starting Materials Market: End use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Cellular Starting Materials Market End use Movement Analysis
• 7.3. Global Cellular Starting Materials Market Size & Trend Analysis, by End use, 2018 to 2030 (USD Million)
• 7.4. Pharmaceutical & Biotechnology Companies
  • 7.4.1. Pharmaceutical & Biotechnology Companies market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Hospitals & Clinical Testing Laboratories
  • 7.5.1. Hospitals & Clinical Testing Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Academic & Research Institutes
  • 7.6.1. Academic & Research Institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Other
  • 7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Cell Analysis Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Competitive scenario
    • 8.4.2.3. Regulatory framework
    • 8.4.2.4. Target disease prevalence
    • 8.4.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Competitive scenario
    • 8.4.3.3. Regulatory framework
    • 8.4.3.4. Target disease prevalence
    • 8.4.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Competitive scenario
    • 8.4.4.3. Regulatory framework
    • 8.4.4.4. Target disease prevalence
    • 8.4.4.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Competitive scenario
    • 8.5.2.3. Regulatory framework
    • 8.5.2.4. Target disease prevalence
    • 8.5.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Competitive scenario
    • 8.5.3.3. Regulatory framework
    • 8.5.3.4. Target disease prevalence
    • 8.5.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Competitive scenario
    • 8.5.4.3. Regulatory framework
    • 8.5.4.4. Target disease prevalence
    • 8.5.4.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Competitive scenario
    • 8.5.5.3. Regulatory framework
    • 8.5.5.4. Target disease prevalence
    • 8.5.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Competitive scenario
    • 8.5.6.3. Regulatory framework
    • 8.5.6.4. Target disease prevalence
    • 8.5.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Competitive scenario
    • 8.5.7.3. Regulatory framework
    • 8.5.7.4. Target disease prevalence
    • 8.5.7.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Competitive scenario
    • 8.5.8.3. Regulatory framework
    • 8.5.8.4. Target disease prevalence
    • 8.5.8.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.9. Denmark
    • 8.5.9.1. Key country dynamics
    • 8.5.9.2. Competitive scenario
    • 8.5.9.3. Regulatory framework
    • 8.5.9.4. Target disease prevalence
    • 8.5.9.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Competitive scenario
    • 8.6.2.3. Regulatory framework
    • 8.6.2.4. Target disease prevalence
    • 8.6.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Competitive scenario
    • 8.6.3.3. Regulatory framework
    • 8.6.3.4. Target disease prevalence
    • 8.6.3.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Competitive scenario
    • 8.6.4.3. Regulatory framework
    • 8.6.4.4. Target disease prevalence
    • 8.6.4.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Competitive scenario
    • 8.6.5.3. Regulatory framework
    • 8.6.5.4. Target disease prevalence
    • 8.6.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Competitive scenario
    • 8.6.6.3. Regulatory framework
    • 8.6.6.4. Target disease prevalence
    • 8.6.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Competitive scenario
    • 8.6.7.3. Target disease prevalence
    • 8.6.7.4. Regulatory framework
    • 8.6.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Competitive scenario
    • 8.7.2.3. Regulatory framework
    • 8.7.2.4. Target disease prevalence
    • 8.7.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Competitive scenario
    • 8.7.3.3. Regulatory framework
    • 8.7.3.4. Target disease prevalence
    • 8.7.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Competitive scenario
    • 8.8.2.3. Regulatory framework
    • 8.8.2.4. Target disease prevalence
    • 8.8.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Competitive scenario
    • 8.8.3.3. Regulatory framework
    • 8.8.3.4. Target disease prevalence
    • 8.8.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Competitive scenario
    • 8.8.4.3. Regulatory framework
    • 8.8.4.4. Target disease prevalence
    • 8.8.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key country dynamics
    • 8.8.5.2. Competitive scenario
    • 8.8.5.3. Regulatory framework
    • 8.8.5.4. Target disease prevalence
    • 8.8.5.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Thermo Fisher Scientific, Inc.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Danaher
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. BD
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Merck KGaA
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Agilent Technologies, Inc.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Bio-Rad Laboratories, Inc.
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Miltenyl Biotech
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Revvity
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. New England Biolabs
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Avantor, Inc.
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives